Gabriel Pardo

Gabriel Pardo

Neurology

825 N.E. 13th St.
Oklahoma City, OK 73104

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Dynamics of Spinal Fluid Immune Cell Alterations Following Cladribine Tablet Treatment in Multiple Sclerosis.

Dynamics of Spinal Fluid Immune Cell Alterations Following Cladribine Tablet Treatment in Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: April 16, 2026

Evaluation of Documented Infections by Provider Specialty in Patients with Multiple Sclerosis Receiving Disease-Modifying Therapies: A Claims Database Analysis.

Evaluation of Documented Infections by Provider Specialty in Patients with Multiple Sclerosis Receiving Disease-Modifying Therapies: A Claims Database Analysis.

Journal: Advances in therapy

Published: December 23, 2025

Eye movement analysis during working memory tasks correlates with cognitive, clinical, and anatomical metrics in multiple sclerosis.

Eye movement analysis during working memory tasks correlates with cognitive, clinical, and anatomical metrics in multiple sclerosis.

Journal: Multiple sclerosis journal - experimental, translational and clinical

Published: December 01, 2025

Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trial.

Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trial.

Journal: JCI insight

Published: November 25, 2025

Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosis.

Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: September 03, 2025

Prospective SARS-CoV-2 Booster Vaccination in Immunosuppressant-Treated Systemic Autoimmune Disease Patients in a Randomized Controlled Trial.

Prospective SARS-CoV-2 Booster Vaccination in Immunosuppressant-Treated Systemic Autoimmune Disease Patients in a Randomized Controlled Trial.

Journal: medRxiv : the preprint server for health sciences

Published: April 08, 2025

Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.

Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.

Journal: Neurology

Published: January 30, 2025

Serum Proteomics Distinguish Subtypes of NMO Spectrum Disorder and MOG Antibody-Associated Disease and Highlight Effects of B-Cell Depletion.

Serum Proteomics Distinguish Subtypes of NMO Spectrum Disorder and MOG Antibody-Associated Disease and Highlight Effects of B-Cell Depletion.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: June 17, 2024

Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis.

Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis.

Journal: JAMA neurology

Published: March 11, 2024

Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases.

Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases.

Journal: JCI insight

Published: February 29, 2024

Obesity intensifies sex-specific interferon signaling to selectively worsen central nervous system autoimmunity in females.

Obesity intensifies sex-specific interferon signaling to selectively worsen central nervous system autoimmunity in females.

Journal: Cell metabolism

Published: January 05, 2024

Thalamic atrophy and dysconnectivity are associated with cognitive impairment in a multi-center, clinical routine, real-word study of people with relapsing-remitting multiple sclerosis.

Thalamic atrophy and dysconnectivity are associated with cognitive impairment in a multi-center, clinical routine, real-word study of people with relapsing-remitting multiple sclerosis.

Journal: NeuroImage. Clinical

Published: January 04, 2024

Showing 1-12 of 43

Last Updated: 09/26/2026